

Office of Regulatory Management  
Economic Review Form

<b>Agency name</b>	Board of Pharmacy, Department of Health Professions
<b>Virginia Administrative Code (VAC) Chapter/Guidance Document citation(s)</b>	N/A 110-14, 110-20, 110-40, 110-45, 110-48, 110-51
<b>Guidance Document title(s)</b>	<ul style="list-style-type: none"> <li>• Proximity of a School or Daycare to a Cannabis Dispensing Facility;</li> <li>• Criminal Background Checks of Material Owners for Pharmaceutical Processor or Cannabis Dispensing Facility Permits;</li> <li>• Contracted Employee Access to a Pharmaceutical Processor;</li> <li>• Approved Chemicals for use as Hydrocarbon or Other Flammable Solvents by Pharmaceutical Processors;</li> <li>• Verification Sources for a Pharmaceutical Processor; and</li> <li>• Cannabis Product Packaging Requirements.</li> </ul>
<b>Action title</b>	Repeal of Guidance Documents related to the Medical Cannabis Program under the Board of Pharmacy
<b>Date this document prepared</b>	December 11, 2023
<b>Regulatory Stage (including Issuance of Guidance Documents)</b>	N/A

**Cost Benefit Analysis**

Complete Tables 1a and 1b for all regulatory actions. You do not need to complete Table 1c if the regulatory action is required by state statute or federal statute or regulation and leaves no discretion in its implementation.

Table 1a should provide analysis for the regulatory approach you are taking. Table 1b should provide analysis for the approach of leaving the current regulations intact (i.e., no further change is implemented). Table 1c should provide analysis for at least one alternative approach. You should not limit yourself to one alternative, however, and can add additional charts as needed.

Report both direct and indirect costs and benefits that can be monetized in Boxes 1 and 2. Report direct and indirect costs and benefits that cannot be monetized in Box 4. See the ORM Regulatory Economic Analysis Manual for additional guidance.

**Table 1a: Costs and Benefits of the Proposed Changes (Primary Option)**

(1) Direct & Indirect Costs & Benefits (Monetized)	There are no direct costs or benefits to this action. The Board loses jurisdiction over the medical cannabis program on January 1, 2024, per statutory change, and these documents will no longer be effective. The program will be run by the Virginia Cannabis Control Authority after that date. Therefore, there is no monetary change as a result of these repeal actions.	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a) \$0	(b) \$0
(3) Net Monetized Benefit	\$0	
(4) Other Costs & Benefits (Non-Monetized)	N/A	
(5) Information Sources		

**Table 1b: Costs and Benefits under the Status Quo (No change to the regulation)**

(1) Direct & Indirect Costs & Benefits (Monetized)	There are no costs of benefits associated with the status quo, although leaving the documents in place would be confusing to the public since the Board of Pharmacy will no longer have jurisdiction over the medical cannabis program as of January 1, 2024.	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a) \$0	(b) \$0
(3) Net Monetized Benefit	\$0	
(4) Other Costs & Benefits (Non-Monetized)	N/A	

(5) Information Sources	
-------------------------	--

**Table 1c: Costs and Benefits under Alternative Approach(es)**

(1) Direct & Indirect Costs & Benefits (Monetized)	There are no alternative approaches, and therefore no costs or benefits to alternative approaches. The Board loses jurisdiction over the medical cannabis program on January 1, 2024, per statutory change, and these documents will no longer be effective. The program will be run by the Virginia Cannabis Control Authority after that date.	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a) \$0	(b) \$0
(3) Net Monetized Benefit	\$0	
(4) Other Costs & Benefits (Non-Monetized)	N/A	
(5) Information Sources		

**Impact on Local Partners**

Use this chart to describe impacts on local partners. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

**Table 2: Impact on Local Partners**

(1) Direct & Indirect Costs & Benefits (Monetized)	There is no impact on local partners.	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a) \$0	(b) \$0
(3) Other Costs & Benefits (Non-Monetized)	\$0	

(4) Assistance	N/A
(5) Information Sources	

**Impacts on Families**

Use this chart to describe impacts on families. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

**Table 3: Impact on Families**

(1) Direct & Indirect Costs & Benefits (Monetized)	There is no impact on families.	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a) \$0	(b) \$0
(3) Other Costs & Benefits (Non-Monetized)	N/A	
(4) Information Sources		

**Impacts on Small Businesses**

Use this chart to describe impacts on small businesses. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

**Table 4: Impact on Small Businesses**

(1) Direct & Indirect Costs & Benefits (Monetized)	There is no impact on small businesses.	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a) \$0	(b) \$0

(3) Other Costs & Benefits (Non-Monetized)	N/A
(4) Alternatives	N/A
(5) Information Sources	

**Changes to Number of Regulatory Requirements**

**Table 5: Regulatory Reduction**

For each individual action, please fill out the appropriate chart to reflect any change in regulatory requirements, costs, regulatory stringency, or the overall length of any guidance documents.

*Change in Regulatory Requirements*

VAC Section(s) Involved	Initial Count	Additions	Subtractions	Net Change

*Cost Reductions or Increases (if applicable)*

VAC Section(s) Involved	Description of Regulatory Requirement	Initial Cost	New Cost	Overall Cost Savings/Increases

*Other Decreases or Increases in Regulatory Stringency (if applicable)*

VAC Section(s) Involved	Description of Regulatory Change	Overview of How It Reduces or Increases Regulatory Burden

*Length of Guidance Documents (only applicable if guidance document is being revised)*

Title of Guidance Document	Original Length	New Length	Net Change in Length
110-14	1 page	0	-1 page
110-20	1 page	0	-1 page
110-40	2 pages	0	-2 pages
110-45	1 page	0	-1 page
110-48	3 pages	0	-3 pages
110-51	1 page	0	-1 page